Despite the outcomes of both the presidential election and the Brexit vote, this could be a banner year for biopharma mergers and acquisitions, according to two new reports.
Biopharma valuations leveled off substantially in 2016, which sets the stage this year for several new divestitures and megadeals, according to a new report from consulting firm EY.
And while initial public offerings were the predominant exit method for small companies back in the biopharma boom years of 2014 and 2015, these days startups will likely favor acquisition over IPO, according to a new report from the life sciences consultancy Trinity Partners.
About the Author Reprints
